Letter to the Editor
I have recently been updating information on the new oral anticoagulants for NPS MedicineWise. I used your article1 as a starting point to see what references have been published since 2013.
In reviewing the pharmacokinetics of apixaban, I got confused and so did some further research. I found a Letter to the Editor on the topic.2 It essentially explains that the commonly quoted number of 50% for renal clearance is flawed due to a calculation error between the primary and secondary source.
Clinical program officer
- Chin PKL, Doogue MP. Long-term prescribing of new oral anticoagulants. Aust Prescr 2016;9:200-4.
- Frost C, Boyd RA. The contribution of apixaban renal clearance to total clearance. J Thromb Thrombolysis 2015;40:521-2.
- Hellfritzsch M, Damkier P, Pottegard A, Gronlykke T, Grove EL. Inconsistencies in reporting of renal elimination among NOACs: the case of apixaban. Pharmacoepidemiol Drug Saf 2016;25:346-8.
- Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81.
- Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs 2016;16:119-27.